Latest & greatest articles for topiramate

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on topiramate or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on topiramate and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for topiramate

1. Topiramate

Topiramate Top results for topiramate - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for topiramate The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

2. Short-term adjunct of topiramate to antipsychotics in schizophrenia improves the psychopathology and has weight maintenance

Short-term adjunct of topiramate to antipsychotics in schizophrenia improves the psychopathology and has weight maintenance Relative to SSRI users, SSRI–statin users have fewer psychiatric hospital contacts and no increase in suicidal behaviour or all-cause mortality | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts

Evidence-Based Mental Health2018

4. Topiramate use early in pregnancy and the risk of oral clefts: A pregnancy cohort study

Topiramate use early in pregnancy and the risk of oral clefts: A pregnancy cohort study 29282333 2017 12 28 1526-632X 2017 Dec 27 Neurology Neurology Topiramate use early in pregnancy and the risk of oral clefts: A pregnancy cohort study. 10.1212/WNL.0000000000004857 10.1212/WNL.0000000000004857 To assess the relative risk of oral clefts associated with maternal use of high and low doses of topiramate during the first trimester for epilepsy and nonepilepsy indications. This population-based (...) study nested in the US 2000-2010 Medicaid Analytic eXtract included a cohort of 1,360,101 pregnant women with a live-born infant enrolled in Medicaid from 3 months before conception through 1 month after delivery. Oral clefts were defined as the presence of a recorded diagnosis in claims during the first 90 days after birth. Women with a topiramate dispensing during the first trimester were compared with those without any dispensing and with an active reference group of women with a lamotrigine

EvidenceUpdates2018

5. Comparison of the effect of topiramate versus gabapentin on neuropathic pain in patients with polyneuropathy: A randomized clinical trial

Comparison of the effect of topiramate versus gabapentin on neuropathic pain in patients with polyneuropathy: A randomized clinical trial 29238506 2018 11 13 2008-5842 9 10 2017 Oct Electronic physician Electron Physician Comparison of the effect of topiramate versus gabapentin on neuropathic pain in patients with polyneuropathy: A randomized clinical trial. 5617-5622 10.19082/5617 Neuropathic pain is one of the most common complaints of neurologic clinics. Neuropathic pain is common (...) and important and has inappropriate complications, and despite their importance, there is no effective treatment for them. Because of the importance of neuropathic pain and safe and effective treatment, in this study, we determined the effect of topiramate versus gabapentin in patients with neuropathic pain. In this randomized clinical trial, 30 patients with pain attributed to neuropathy who had at least one month of neuropathic pain in one area, were randomized to receive either gabapentin, titrated from

Electronic physician2017 Full Text: Link to full Text with Trip Pro

6. Cardiometabolic Disease Staging Predicts Effectiveness of Weight Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release

Cardiometabolic Disease Staging Predicts Effectiveness of Weight Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release 28455281 2017 04 29 2017 04 29 1935-5548 2017 Apr 28 Diabetes care Diabetes Care Cardiometabolic Disease Staging Predicts Effectiveness of Weight Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release. dc170088 (...) 10.2337/dc17-0088 To assess the ability of medication-assisted weight loss to prevent diabetes as a function of the baseline weighted Cardiometabolic Disease Staging (CMDS) score. We pooled data from 3,040 overweight and obese participants in three randomized controlled trials-CONQUER, EQUIP, and SEQUEL- assessing efficacy and safety of phentermine/topiramate extended release (ER) for weight loss. In these double-blind phase III trials, overweight/obese adult patients were treated with a lifestyle

EvidenceUpdates2017

7. Topiramate monotherapy for juvenile myoclonic epilepsy.

Topiramate monotherapy for juvenile myoclonic epilepsy. BACKGROUND: Topiramate is a newer broad-spectrum antiepileptic drug (AED). Some studies have shown the benefits of topiramate monotherapy in the treatment of juvenile myoclonic epilepsy (JME). However, there are no current systematic reviews to determine the efficacy and tolerability of topiramate monotherapy in people with JME. This is an updated version of the original Cochrane Review published in Issue 12, 2015. OBJECTIVES: To evaluate (...) the efficacy and tolerability of topiramate monotherapy in the treatment of JME. SEARCH METHODS: For the latest update, on 21 February 2017 we searched Cochrane Epilepsy's Specialized Register, CENTRAL, MEDLINE, and ClinicalTrials.gov. We also searched ongoing trials registers, reference lists and relevant conference proceedings, and contacted study authors and pharmaceutical companies. SELECTION CRITERIA: We included randomized controlled trials (RCTs) investigating topiramate monotherapy versus placebo

Cochrane2017

8. Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine.

Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine. BACKGROUND: Which medication, if any, to use to prevent the headache of pediatric migraine has not been established. METHODS: We conducted a randomized, double-blind, placebo-controlled trial of amitriptyline (1 mg per kilogram of body weight per day), topiramate (2 mg per kilogram per day), and placebo in children and adolescents 8 to 17 years of age with migraine. Patients were randomly assigned in a 2:2:1 ratio (...) in the amitriptyline group, 130 in the topiramate group, and 66 in the placebo group). The trial was concluded early for futility after a planned interim analysis. There were no significant between-group differences in the primary outcome, which occurred in 52% of the patients in the amitriptyline group, 55% of those in the topiramate group, and 61% of those in the placebo group (amitriptyline vs. placebo, P=0.26; topiramate vs. placebo, P=0.48; amitriptyline vs. topiramate, P=0.49). There were also no significant

NEJM2016

9. Topiramate for acute affective episodes in bipolar disorder in adults.

Topiramate for acute affective episodes in bipolar disorder in adults. BACKGROUND: Bipolar disorder is a common recurrent illness with high levels of chronicity. Previous trials have suggested that the anticonvulsant topiramate may be efficacious in bipolar disorder. This is an update of a previous Cochrane review (last published 2006) on the role of topiramate in bipolar disorder. OBJECTIVES: To assess the effects of topiramate for acute mood episodes in bipolar disorder in adults compared (...) and reference lists, and correspondence with authors and pharmaceutical companies. SELECTION CRITERIA: Randomised controlled trials comparing topiramate with placebo or with active agents in the treatment of acute mood episodes in adult male and female patients with bipolar disorder. DATA COLLECTION AND ANALYSIS: Two review authors independently performed data extraction and methodological quality assessment. For analysis, we used odds ratio (OR) for binary efficacy outcomes and mean difference (MD

Cochrane2016

10. Adverse effects of galantamine, topiramate and cotrimoxazole

Adverse effects of galantamine, topiramate and cotrimoxazole Prescrire IN ENGLISH - Spotlight ''In the July issue of Prescrire International: adverse effects of galantamine, topiramate and cotrimoxazole'', 1 July 2015 {1} {1} {1} | | > > > In the July issue of Prescrire International: adverse effects of galantamine, topiramate and cotrimoxazole Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |  (...)  |   |   |  Spotlight In the July issue of Prescrire International: adverse effects of galantamine, topiramate and cotrimoxazole FREE DOWNLOAD All in one sample page: from serious skin reactions with Alzheimer's drug galantamine and visual field defects with topiramate to the potentially deadly effects of the antibiotic cotrimoxazole, either alone or when coadministrered with an ACE inhibitor or ARB. Sample page available for free download. Cotrimoxazole + an ACE

Prescrire2015

11. Is immediate-release topiramate an effective treatment for adult obesity?

Is immediate-release topiramate an effective treatment for adult obesity? Is immediate-release topiramate an effective treatment for adult obesity? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Is immediate-release topiramate an effective treatment for adult obesity? View/ Open Date 2014-12 Format Metadata Abstract Q (...) : Is immediate-release topiramate an effective treatment for adult obesity? Evidence-Based Answer: Yes. Topiramate (at daily doses of 64-400 mg) produces an average 5.34 kg of additional weight loss compared with placebo (95% confidence interval [CI], -6.12 to -4.56) in overweight to obese adults for periods of 16 to 60 weeks (strength of recommendation [SOR]: A, meta-analyses of randomized controlled trials [RCTs]). Topiramate increases the chances of losing 5% or more of aseline body weight (BBW

Clinical Inquiries2015

12. Topiramate + phentermine (Qsiva and other brands): an excessively dangerous appetite-suppressant combination

Topiramate + phentermine (Qsiva and other brands): an excessively dangerous appetite-suppressant combination Prescrire IN ENGLISH - Spotlight: Archive ''Topiramate + phentermine (Qsiva° and other brands): an excessively dangerous appetite-suppressant combination'', 1 March 2013 {1} {1} {1} | | > > > Topiramate + phentermine (Qsiva° and other brands): an excessively dangerous appetite-suppressant combination Spotlight: Archives Every month, the subjects in Prescrire’s Spotlight. 2013 :   (...) |   |  Spotlight Archives Topiramate + phentermine (Qsiva° and other brands): an excessively dangerous appetite-suppressant combination FEATURED REVIEW Overweight and obese patients must not be exposed to the topiramate + phentermine combination. No beneficial impact on clinical complications of obesity has been demonstrated. A portion of the weight lost is regained after treatment withdrawal. And numerous serious adverse effects have already been observed. Full review (4 pages) available

Prescrire2014

13. Topiramate Treatment for Heavy Drinkers: Moderation by a GRIK1 Polymorphism

Topiramate Treatment for Heavy Drinkers: Moderation by a GRIK1 Polymorphism 24525690 2014 04 01 2014 05 14 2016 12 15 1535-7228 171 4 2014 Apr The American journal of psychiatry Am J Psychiatry Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. 445-52 10.1176/appi.ajp.2013.13081014 Topiramate has been shown to reduce drinking and heavy drinking in individuals with alcohol dependence whose goal was to stop drinking. The authors evaluated the efficacy and tolerability (...) of topiramate in heavy drinkers whose treatment goal was to reduce drinking to safe levels. A total of 138 individuals (62.3% men) were randomly assigned to receive 12 weeks of treatment with topiramate (N=67), at a maximal daily dose of 200 mg, or matching placebo (N=71). Both groups received brief counseling to reduce drinking and increase abstinent days. It was hypothesized that topiramate-treated patients would be better able to achieve these goals, and it was predicted that based on prior research

EvidenceUpdates2014 Full Text: Link to full Text with Trip Pro

14. Topiramate

Topiramate USE OF TOPIRAMATE IN PREGNANCY 0344 892 0909 USE OF TOPIRAMATE IN PREGNANCY (Date of issue: December 2014 , Version: 2.2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Topiramate is an anticonvulsant used either in monotherapy (...) or as adjunctive therapy in the treatment of generalised tonic-clonic seizures, focal seizures with or without secondary generalisation, and seizures associated with Lennox-Gastaut syndrome. Topiramate is also licensed for the prophylaxis of migraine, and in the United States for weight loss. The majority of the available data relates to use of topiramate for the control of maternal epilepsy. Gestational topiramate exposure has been associated with orofacial clefts in the offspring. However, data

UK Teratology Information Service2014

16. Trokendi XR (topiramate) Extended-Release Capsules

Trokendi XR (topiramate) Extended-Release Capsules Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Trokendi XR (topiramate) Extended-Release Capsules Company: Supernus Pharmaceuticals, Inc. Application No.: 201635 Approval Date: 8/16/2013 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

FDA - Drug Approval Package2013

17. Two Center, Randomized Pilot Study of Migraine Prophylaxis Comparing Paradigms Using Pre-Emptive Frovatriptan or Daily Topiramate: Research and Clinical Implications

Two Center, Randomized Pilot Study of Migraine Prophylaxis Comparing Paradigms Using Pre-Emptive Frovatriptan or Daily Topiramate: Research and Clinical Implications 22188311 2012 05 08 2013 05 10 2015 11 19 1526-4610 52 5 2012 May Headache Headache Two center, randomized pilot study of migraine prophylaxis comparing paradigms using pre-emptive frovatriptan or daily topiramate: research and clinical implications. 749-64 10.1111/j.1526-4610.2011.02054.x To compare the efficacy and clinical (...) benefit of 2 paradigms of migraine prevention using pre-emptive frovatriptan and daily topiramate. The study compares the paradigms of pre-emptive use of frovatriptan, a drug approved for acute migraine, and the daily use of topiramate, a Federal Drug Administration-approved and -accepted standard for migraine prophylaxis. Traditionally, preventive treatment of migraine required daily medication. However, recent studies suggest that pre-emptive prophylaxis may be beneficial to those migraineurs who

EvidenceUpdates2012

18. Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials

Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials Kramer CK, Leitao CB, Pinto LC, Canani LH, Azevedo MJ, Gross JL CRD summary This generally well-conducted review found that topiramate may be a useful adjunctive treatment for obesity, and may play a role (...) in the treatment of obesity in individuals with type 2 diabetes mellitus. The authors' conclusions are likely to be reliable. Authors' objectives To assess the potential benefits and harms of topiramate in the treatment of obesity. Searching MEDLINE, EMBASE, the Cochrane Library and ClinicalTrials.gov were searched up to April 2010 for relevant studies; search terms were reported. Reference lists of the retrieved articles were checked to identify additional references. There were no language restrictions

DARE.2012

19. Randomised controlled trial: The combination of phentermine and topiramate is an effective adjunct to diet and lifestyle modification for weight loss and measures of comorbidity in overweight or obese adults with additional metabolic risk factors

Randomised controlled trial: The combination of phentermine and topiramate is an effective adjunct to diet and lifestyle modification for weight loss and measures of comorbidity in overweight or obese adults with additional metabolic risk factors The combination of phentermine and topiramate is an effective adjunct to diet and lifestyle modification for weight loss and measures of comorbidity in overweight or obese adults with additional metabolic risk factors | Evidence (...) and topiramate is an effective adjunct to diet and lifestyle modification for weight loss and measures of comorbidity in overweight or obese adults with additional metabolic risk factors Article Text Therapeutics Randomised controlled trial The combination of phentermine and topiramate is an effective adjunct to diet and lifestyle modification for weight loss and measures of comorbidity in overweight or obese adults with additional metabolic risk factors Amanda G Powell 1 , Caroline M Apovian 1 , Louis J

Evidence-Based Medicine (Requires free registration)2012

20. Qsymia (phentermine and topiramate extended-release)

Qsymia (phentermine and topiramate extended-release) Drug Approval Package: Qsymia (phentermine and topiramate extended-release) NDA #22580Orig1s000 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Qsymia (phentermine and topiramate extended-release) Capsules CIV Company: Vivus, Inc. Application No.: 22580Orig1s000 Approval Date: 07/17/2012 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634

FDA - Drug Approval Package2012